These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 1421051)

  • 41. Influence of arterio-venous haemofiltration on teicoplanin elimination.
    Hillaire-Buys D; Peyriere H; Lobjoie E; Bres J; Ossart M; Despaux E
    Br J Clin Pharmacol; 1995 Jul; 40(1):95-7. PubMed ID: 8527277
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An initial dosing method for teicoplanin based on the area under the serum concentration time curve required for MRSA eradication.
    Kanazawa N; Matsumoto K; Ikawa K; Fukamizu T; Shigemi A; Yaji K; Shimodozono Y; Morikawa N; Takeda Y; Yamada K
    J Infect Chemother; 2011 Apr; 17(2):297-300. PubMed ID: 20714913
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetics of 14C-teicoplanin in healthy volunteers.
    Buniva G; Del Favero A; Bernareggi A; Patoia L; Palumbo R
    J Antimicrob Chemother; 1988 Jan; 21 Suppl A():23-8. PubMed ID: 2965128
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetics of dalbavancin in patients with renal or hepatic impairment.
    Marbury T; Dowell JA; Seltzer E; Buckwalter M
    J Clin Pharmacol; 2009 Apr; 49(4):465-76. PubMed ID: 19318696
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics of oral and intravenous dolasetron mesylate in patients with renal impairment.
    Dimmitt DC; Shah AK; Arumugham T; Cramer MB; Halstenson C; Horton M; Weir SJ
    J Clin Pharmacol; 1998 Sep; 38(9):798-806. PubMed ID: 9753207
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Physiologically Based Pharmacokinetic Modeling and Dose Adjustment of Teicoplanin in Pediatric Patients With Renal Impairment.
    Xu J; Lin R; Chen Y; You X; Huang P; Lin C
    J Clin Pharmacol; 2022 May; 62(5):620-630. PubMed ID: 34761398
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and pharmacokinetics of teicoplanin in hemodialysis patients.
    Beckers B; Brodersen HP; Stolpmann RM; Jansen G; Larbig D
    Infection; 1993; 21(1):71-4. PubMed ID: 8449588
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetics and safety of single intravenous infusions of the adenosine agonist, AMP 579, in patients with end-stage renal insufficiency.
    Zannikos PN; Jensen BK; Boutouyrie BX; Tripp L; Yongyi L; McGowan T; Waldman SA; Greenberg HE
    J Clin Pharmacol; 2000 Jul; 40(7):745-51. PubMed ID: 10883416
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetics of teicoplanin in burn patients.
    Potel G; Moutet J; Bernareggi A; Le Normand Y; Meigner M; Baron D
    Scand J Infect Dis Suppl; 1990; 72():29-34. PubMed ID: 2151064
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Change of teicoplanin loading dose requirement for incremental increases of systemic inflammatory response syndrome score in the setting of sepsis.
    Nakano T; Nakamura Y; Takata T; Irie K; Sano K; Imakyure O; Mishima K; Futagami K
    Int J Clin Pharm; 2016 Aug; 38(4):908-14. PubMed ID: 27125378
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Population Pharmacokinetics of Teicoplanin and Its Dosing Recommendations for Neutropenic Patients With Augmented Renal Clearance for Hematological Malignancies.
    Sako KI; Nakamaru Y; Ikawa K; Maeda T; Goto S; Ishihara Y; Kato Y; Matsuda Y
    Ther Drug Monit; 2021 Aug; 43(4):519-526. PubMed ID: 34250964
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Population pharmacokinetics of teicoplanin and attainment of pharmacokinetic/pharmacodynamic targets in adult patients with haematological malignancy.
    Byrne CJ; Roberts JA; McWhinney B; Ryder SA; Fennell JP; O'Byrne P; Deasy E; Egan S; Desmond R; Enright H; D'Arcy DM; McHugh J
    Clin Microbiol Infect; 2017 Sep; 23(9):674.e7-674.e13. PubMed ID: 28267636
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetics of multiple doses of teicoplanin in Chinese elderly critical patients.
    Wang S; Lin F; Ruan J; Ye H; Wang L
    Expert Rev Clin Pharmacol; 2018 May; 11(5):537-541. PubMed ID: 29506414
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Steady-state pharmacokinetics and safety of donepezil HCl in subjects with moderately impaired renal function.
    Nagy CF; Kumar D; Cullen EI; Bolton WK; Marbury TC; Gutierrez MJ; Hutman HW; Pratt RD
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):18-24. PubMed ID: 15496219
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Therapeutic monitoring of teicoplanin in a severely burned patient].
    Lesne-Hulin A; Bourget P; Le Bever H; Ainaud P; Carsin H
    Ann Fr Anesth Reanim; 1997; 16(4):374-7. PubMed ID: 9750583
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An evaluation of the pharmacokinetics of donepezil HCl in patients with moderately to severely impaired renal function.
    Tiseo PJ; Foley K; Friedhoff LT
    Br J Clin Pharmacol; 1998 Nov; 46 Suppl 1(Suppl 1):56-60. PubMed ID: 9839768
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetics of fosinopril in patients with various degrees of renal function.
    Hui KK; Duchin KL; Kripalani KJ; Chan D; Kramer PK; Yanagawa N
    Clin Pharmacol Ther; 1991 Apr; 49(4):457-67. PubMed ID: 1826651
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study.
    Lal R; Sukbuntherng J; Luo W; Chen D; Blumenthal R; Ho J; Cundy KC
    Clin Ther; 2012 Jan; 34(1):201-13. PubMed ID: 22206794
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical pharmacokinetics of teicoplanin and aminophylline during cotreatment with both medicaments.
    Angrisani M; Cazzola M; Loffreda A; Losasso C; Lucarelli C; Rossi F
    Int J Clin Pharmacol Res; 1992; 12(4):165-71. PubMed ID: 1297639
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The pharmacokinetics of teicoplanin in infants and children.
    Reed MD; Yamashita TS; Myers CM; Blumer JL
    J Antimicrob Chemother; 1997 Jun; 39(6):789-96. PubMed ID: 9222049
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.